AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02891174
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
Trial: NCT00445081
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00445081
Drug: Ciclosporine A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04124939
Drug: OnabotulinumtoxinA 100 Units
RxNorm normalized name: onabotulinumtoxinA 100 units injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
Trial: NCT00266799
Drug: Pegylated liposomal doxorubicin (SCH 200746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
Trial: NCT00266799
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
Trial: NCT02250326
Drug: Duravalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00248625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
Trial: NCT00023959
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04851769
Drug: PCSK9 inhibitor plus statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
Trial: NCT04851769
Drug: standard statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
Trial: NCT01327625
Drug: azithromycin + N-acetylcystein + inhaled corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Azithromycin 500mg qd x 1 week --\> 250mg qod x 6 months~* N-acetylcystein 200mg tid x 6 months~* Fluticasone 250mcg puff x2/day x 6 months
Trial: NCT02603146
Drug: HCQ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described. Dosing will be based upon Screening IBW.
Trial: NCT04375150
Drug: Tyrosine kinase inhibitor (TKI)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TKIs
Trial: NCT04375150
Drug: Immuno-oncology (IO)
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOs
Trial: NCT02039115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
Trial: NCT04633447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously.
Trial: NCT04145310
Drug: BOL-DP-o-04 + SCO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual drops
Trial: NCT04145310
Drug: Placebo + SCO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual drops
Trial: NCT01515813
Drug: Pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 40 mg tablet of Pravastatin sodium taken orally once daily.
Trial: NCT01515813
Drug: Pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
Trial: NCT01234337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
Trial: NCT01234337
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
Trial: NCT00580827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo.
Trial: NCT00580827
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: disulfiram at 62.5 mg/day for 12 weeks.
Trial: NCT00580827
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram at 125 mg/day for 12 weeks.
Trial: NCT00580827
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: disulfiram at 250 mg/day for 12 weeks.
Trial: NCT01978548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as 2 oral tablets once daily.
Trial: NCT00572169
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given into the vein (IV) by a continuous infusion through a central catheter
Trial: NCT00006037
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01365195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
Trial: NCT01825759
Drug: danshen dripping pill
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01317368
Drug: Naropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Trial: NCT01317368
Drug: Naropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Trial: NCT03767933
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/kg, maximum 600mg; Oral liquid
Trial: NCT03767933
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg, maximum 1000mg; Oral liquid
Trial: NCT03767933
Drug: Acetaminophen placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid
Trial: NCT04750824
Drug: other systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: other systemic therapy
Trial: NCT03859024
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen tablet
Trial: NCT03859024
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen tablet
Trial: NCT01322711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet
Trial: NCT00907426
Drug: Vehicle solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
Trial: NCT02280265
Drug: Recombinant Human Coagulation Factor VIII for injection
RxNorm normalized name: coagulation factor VIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
Trial: NCT02584660
Drug: Standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Trial: NCT00969462
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: measurements of serum Doxorubicin levels
Trial: NCT00171691
Drug: Diclofenac Topical Sodium Gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02297620
Drug: Suglat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01089075
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg po for 7 days (2 tablets)
Trial: NCT04076293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
Trial: NCT04244253
Drug: OPC-64005 20 mg , Once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active, High Dose
Trial: NCT04244253
Drug: OPC-64005 10 mg , Once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active, Low Dose
Trial: NCT04244253
Drug: Placebo, Once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00434876
Drug: Placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive or inert pill which will be used as a comparator.
Trial: NCT00780676
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg by mouth twice daily.
Trial: NCT00212355
Drug: NPC-02
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zinc acetate
Trial: NCT00320619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Trial: NCT02753283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-annual saline injection
Trial: NCT01288742
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 10-mg tablet for 1 day (Trt C).
Trial: NCT01288742
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
Trial: NCT01288742
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 150-mg capsule once daily for 7 days (Trts B and D).
Trial: NCT01711359
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT01711359
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally every day
Trial: NCT03124524
Drug: ethinylestradiol and drospirenone
RxNorm normalized name: drospirenone and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
Trial: NCT02517502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched, blinded placebo
Trial: NCT04231773
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 parts per million dosage
Trial: NCT04231773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
Trial: NCT03683069
Drug: Eplerenone vs Amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
Trial: NCT03070054
Drug: 20ml 0.25% bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
Trial: NCT03088345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
Trial: NCT00671658
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 by vein
Trial: NCT01888367
Drug: DFA-02 Antibiotic Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01888367
Drug: DFA-02 Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00671658
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 by vein
Trial: NCT00671658
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8
Trial: NCT00671658
Drug: Solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg by vein for Courses 2,4,6,8
Trial: NCT01962935
Drug: AZD4721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
Trial: NCT01962935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A - multiple ascending dose daily
Trial: NCT01962935
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B - one dose decided after part A, twice a day
Trial: NCT03195231
Drug: Wuling Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
Trial: NCT03195231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
Trial: NCT02155725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As soon as possible and within 30 min following the start of prostaglandin infusion
Trial: NCT03618160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
Trial: NCT03744975
Drug: LCZ 696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
Trial: NCT03744975
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1oral Placebo capsule
Trial: NCT03444831
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
Trial: NCT00660829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01593826
Drug: Charcoal and Symbicort Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT01593826
Drug: Symbicort Turbuhaler forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT02712346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One inactive pill daily for twelve weeks
Trial: NCT04375605
Drug: 5-Fluorouracil during radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day 1 - 33: 225 mg/m²/day IV continuously
Trial: NCT02250222
Drug: Placebo (Captisol ®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
Trial: NCT03023449
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide gas
Trial: NCT03658213
Drug: ZOLADEX 10.8 mg
RxNorm normalized name: Zoladex 10.8 MG Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
Trial: NCT03658213
Drug: ZOLADEX 3.6mg
RxNorm normalized name: Zoladex 3.6mg Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
Trial: NCT00986817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
Trial: NCT03385395
Drug: OctaAlpha1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
Trial: NCT06749977
Drug: Remineralization with SAP11-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The WSL were treated with SAP11-4 according to the manufacturer's instruction
Trial: NCT01809158
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01809158
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03525379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
Trial: NCT01004861
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered once or twice daily, continuous dosing
Trial: NCT04361695
Drug: Ketoprophenum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprophenum
Trial: NCT04361695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03436576
Drug: Autologous Serum 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of 1 drop of Autologous Serum 50% four times a day
Trial: NCT05178745
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
Trial: NCT00471055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02554721
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00247052
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac 50 mg bid versus placebo bid